JAMA

JAMA JAMA is an international peer-reviewed general medical journal published weekly online and in print.

The official page for JAMA http://jama.com, an international, peer-reviewed journal published weekly online and in print.

đź“Š Research Summary: For infants with opioid withdrawal syndrome cared for with the approach, symptom-based opioid do...
06/24/2026

đź“Š Research Summary: For infants with opioid withdrawal syndrome cared for with the approach, symptom-based opioid dosing shortened time to medical readiness for discharge vs a scheduled opioid taper, without differences in safety through 3 months.

This study assessed whether a symptom-based dosing strategy for opioid treatment reduces time to medical readiness for discharge compared with scheduled opioid taper in infants with neonatal opioid withdrawal syndrome (NOWS) cared for with the Eat, Sleep, Console approach (ESC) or Finnegan-based...

đź’¬ Editorial by Matthew Grossman, MD1, Adam Berkwitt, MD, and Rachel Osborn, MD: In a multicenter randomized clinical tri...
06/24/2026

💬 Editorial by Matthew Grossman, MD1, Adam Berkwitt, MD, and Rachel Osborn, MD: In a multicenter randomized clinical trial across diverse US hospitals, symptom‑based dosing for infants treated for was associated with faster readiness for discharge and fewer opioid doses vs scheduled tapering. These findings support symptom‑based dosing with ESC‑based assessment as an evidence‑based standard with implications for reducing hospital length of stay and health care resource use.

Neonatal opioid withdrawal syndrome (NOWS) remains a consequential downstream effect of the ongoing opioid epidemic in the US. Although we have improved both access and approach to medical management of opioid use disorder in pregnancy, exposure confers a risk of withdrawal to the infant, regardless...

Among infants with neonatal opioid withdrawal syndrome cared for with the approach, symptom-based opioid dosing was as...
06/24/2026

Among infants with neonatal opioid withdrawal syndrome cared for with the approach, symptom-based opioid dosing was associated with a shorter time to medical readiness for discharge than a scheduled opioid taper. The trial found no differences in safety outcomes through 3 months of age, supporting symptom-based dosing as a clinically effective option when pharmacologic treatment is needed.

This crossover randomized clinical trial examines the effect of symptom-based dosing vs scheduled opioid taper on time to medical readiness for discharge

Address

330 N Wabash Ave
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category